Evidence map›Paper›PMID 40316962›Full record

ArticleCardiovascular diabetology2025

CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes.

Oliver Schnell, Jaime Almandoz, Lisa Anderson, Katharine Barnard-Kelly, Tadej Battelino, Matthias Blüher, Luca Busetto, Doina Catrinou, Antonio Ceriello, Xavier Cos and 40 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

50 authors.

Oliver SchnellForschergruppe Diabetes e. V., Helmholtz Center Munich, Ingolstaedter Landstraße 1, 85764, Neuherberg (Munich), Germany. oliver.schnell@lrz.uni-muenchen.de.
Jaime AlmandozDivision of Endocrinology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Lisa AndersonMolecular and Clinical Sciences Research Institute, St. George's University of London, London, UK.
Katharine Barnard-KellySouthern Health NHS Foundation Trust, Southampton, UK.
Tadej BattelinoUniversity Medical Center, Ljubljana, Slovenia.
Matthias BlüherHelmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Zentrum München at the University of Leipzig and University Hospital Leipzig, Leipzig, Germany.
Luca BusettoDepartment of Medicine (DIMED), University of Padova, Padua, Italy.
Doina CatrinouFaculty of Medicine, Ovidius University of Constanta, Constanta, Romania.
Antonio CerielloIRCCS MultiMedica, Milan, Italy.
Xavier CosDAP Cat Research Group, Foundation University Institute for Primary Health Care Research Jordi Gol i Gorina, Barcelona, Spain.
Thomas DanneNOVA Medical School, Lisbon, Portugal.
Colin M DayanCardiff University School of Medicine, Cardiff, UK.
Stefano Del PratoInterdisciplinary Research Center "Health Science", Sant'Anna School of Advanced Studies, Pisa, Italy.
Beatriz Fernández-FernándezDivision of Nephrology and Hypertension, University Hospital Fundación Jiménez Díaz, Madrid, Spain.
Paola FiorettoFaculty of Medicine, University of Padova, Padua, Italy.
Thomas ForstCRS Clinical Research Services Mannheim GmbH, Mannheim, Germany.
James R GavinEmory University School of Medicine, Atlanta, GA, USA.
Francesco GiorginoDepartment of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, Bari, Italy.
Per-Henrik GroopDepartment of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Igor A HarschDivision of Endocrinology and Metabolism, Department of Internal Medicine II, Thuringia Clinic Saalfeld "Georgius Agricola", Saalfeld, Germany.
Hiddo J L HeerspinkDepartment of Clinical Pharmacy and Pharmacology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Lutz HeinemannScience Consulting in Diabetes GmbH, Dusseldorf, Germany.
Mahmoud IbrahimEDC, Centre for Diabetes Education, Charlotte, USA.
Michel JadoulDivision of Nephrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
Sarah JarvisGeneral Practitioner, London, UK.
Linong JiPeking University People's Hospital, Xicheng District, Beijing, China.
Naresh KanumilliManchester University Foundation Trust, Manchester, UK.
Mikhail KosiborodDepartment of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA.
Ulf LandmesserDepartment of Cardiology Angiology and Intensive Care Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany.
Sofia MacieiraSciarc GmbH, Baierbrunn, Germany.
Boris MankovskyDepatment of Diabetology, Shupyk National Healthcare University of Ukraine, Kiev, Ukraine.
Nikolaus MarxClinic for Cardiology, Pneumology, Angiology and Internal Intensive Care Medicine (Medical Clinic I), RWTH Aachen University Hospital, Aachen, Germany.
Chantal MathieuDepartment of Endocrinology, Catholic University of Louvain, Louvain, Belgium.
Barbara McGowanGuy's and St Thomas' Hospital, Kings College London, London, UK.
Tatjana MilenkovicUniversity Clinic of Endocrinology, Diabetes and Metabolic Diseases, Skopje, North Macedonia.
Othmar MoserInstitute of Sports Science, University of Bayreuth, Bayreuth, Germany.
Dirk Müller-WielandDepartment of Medicine I, University Hospital Aachen, Aachen, Germany.
Nikolaos PapanasDiabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
Dipesh C PatelRoyal Free London, University College London, London, UK.
Andreas F H PfeifferDepartment of Endocrinology and Metabolic Diseases, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.
Dario RahelićVuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases at Merkur University Hospital, Zagreb, Croatia.
Helena W RodbardEndocrine and Metabolic Consultants, Rockville, MD, USA.
Lars RydénDepartment of Medicine K2, Karolinska Institute, Stockholm, Sweden.
Elke SchaeffnerInstitute of Public Health, Charité Universitätsmedizin Berlin, Berlin, Germany.
C Wendy SpearmanDivision of Hepatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Alin StirbanAsklepios Klinik Birkenwerder, Birkenwerder, Germany.
Frank TackeDepartment of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany.
Pinar TopseverDepartment of Family Medicine, Acıbadem Mehmet Ali Aydınlar University School of Medicine, Istanbul, Turkey.
Luc Van GaalDepartment of Endocrinology-Diabetology and Metabolism, Antwerp University Hospital, Antwerp, Belgium.
Eberhard StandlForschergruppe Diabetes e. V., Helmholtz Center Munich, Ingolstaedter Landstraße 1, 85764, Neuherberg (Munich), Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 10th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on December 5-6, 2024. This year, discussions about cardiovascular (CV) and kidney outcome trials centered on the recent findings from studies involving empagliflozin (EMPACT-MI), semaglutide (STEP-HFpEF-DM and FLOW), tirzepatide (SURMOUNT-OSA and SUMMIT), and finerenone (FINEARTS-HF). These studies represent significant advances in reducing the risk of major adverse cardiovascular events (MACE) and improving metabolic outcomes in heart failure with preserved ejection fraction (HFpEF), chronic kidney disease (CKD), and obstructive sleep apnea (OSA). The congress also comprised sessions on novel and established therapies for managing HFpEF, CKD, and obesity; guidelines for managing CKD and metabolic dysfunction-associated steatotic liver disease (MASLD); organ crosstalk and the development of cardio-kidney-metabolic (CKM) syndrome; precision medicine and person-centered management of diabetes, obesity, cardiovascular disease (CVD) and CKD; early detection of type 1 diabetes (T1D) and strategies to delay its onset; continuous glucose monitoring (CGM) and automated insulin delivery (AID); cardiovascular autonomic neuropathy (CAN) and the diabetic heart; and the role of primary care in the early detection, prevention and management of CKM diseases. The contribution of environmental plastic pollution to CVD risk, the increasing understanding of the efficacy and safety of incretin therapies in the treatment of CKM diseases, and the latest updates on nutrition strategies for CKM management under incretin-based therapies were also topics of interest for a vast audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians, who actively engaged in online discussions. The 11th CVOT Summit will be held virtually on November 20-21, 2025 ( http://www.cvot.org ).

Indexed as

Cardiovascular DiseasesKidneyRenal Insufficiency, ChronicCongresses as TopicHumansRisk AssessmentRisk FactorsTreatment OutcomeCardiovascular diseaseCGMChronic kidney diseaseCKMDiabetesFinerenoneGLP-1 RAGuidelinesHeart failureMASLDObesitySGLT2 inhibitorTirzepatide

Identifiers

PMID40316962
PMCPMC12048985

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.